Detalhe da pesquisa
1.
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
Diabetes Obes Metab
; 25(5): 1372-1384, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700391
2.
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Circulation
; 139(11): 1384-1395, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586757
3.
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Cardiovasc Diabetol
; 19(1): 176, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050931
4.
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Diabetes Obes Metab
; 22(4): 631-639, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31789445
5.
Development and validation of algorithms to identify newly diagnosed type 1 and type 2 diabetes in pediatric population using electronic medical records and claims data.
Pharmacoepidemiol Drug Saf
; 28(2): 234-243, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30677205
6.
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Age Ageing
; 48(6): 859-866, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31579904
7.
Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
Pediatr Diabetes
; 19(4): 640-648, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29171139
8.
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Diseaseã- Results From EMPA-REG OUTCOME®.
Circ J
; 81(2): 227-234, 2017 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28025462
9.
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Diabetologia
; 59(9): 1860-70, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27316632
10.
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Circulation
; 138(17): 1904-1907, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30354665
11.
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Strokeã- Reply.
Circ J
; 81(6): 899, 2017 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28496049
12.
Anthropometry, metabolic control, and follow-up in children and adolescents with type 1 diabetes mellitus and biopsy-proven celiac disease.
J Pediatr
; 158(4): 589-593.e2, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21051047
13.
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Adv Ther
; 37(8): 3463-3484, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32372290
14.
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
ESC Heart Fail
; 7(6): 3910-3918, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32909680
15.
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
J Hypertens
; 38(9): 1829-1840, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32618884
16.
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
Lancet Diabetes Endocrinol
; 8(12): 949-959, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217335
17.
Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Adv Ther
; 36(10): 2769-2782, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31444706
18.
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Clin Ther
; 41(10): 2021-2040.e11, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31561882
19.
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
J Diabetes Investig
; 10(2): 418-428, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30099847
20.
Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus--data from a German/Austrian multicentre survey.
Pediatr Diabetes
; 9(6): 546-53, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18713134